CP-870893 / Pfizer  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CP-870893 / Pfizer
ACTRN12609000294257: CD-40 activating antibody (CP-870,893) in combination with cisplatin and pemetrexed in unresectable malignant mesothelioma: a phase Ib study

Completed
1
15
 
Sir Charles Gairdner Hospital, Pfizer Australia (research grant-in-aid for investigator initiated study)
unresectable malignant pleural mesothelioma
 
 

Download Options